Summary
This 8-K filing from Edwards Lifesciences (EW) details several key events that occurred around their 2023 Annual Meeting of Stockholders on May 10th, 2023. Most notably, the company announced an increase in CEO Bernard J. Zovighian's annual base salary to $1,050,000 and an incentive pay target of $1,470,000. This compensation adjustment reflects his prior appointment as Chief Executive Officer. Furthermore, the filing reports on the outcomes of various shareholder proposals. All director nominees were elected, and shareholders approved the company's executive compensation on an advisory basis, favoring annual "say-on-pay" votes. A significant amendment to the company's Certificate of Incorporation to provide exculpation for officers, as permitted by Delaware law, was also approved by stockholders. However, a shareholder proposal requesting an independent board chairman policy was not approved. The appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for fiscal year 2023 was also ratified.
Key Highlights
- 1CEO Bernard J. Zovighian's annual base salary increased to $1,050,000, with an incentive pay target of $1,470,000.
- 2All director nominees presented at the 2023 Annual Meeting were elected.
- 3Stockholders approved the company's executive compensation on an advisory basis ('say-on-pay').
- 4Shareholders approved an amendment to the Certificate of Incorporation for officer exculpation.
- 5An advisory vote on the frequency of executive compensation votes resulted in 'one year' as the preferred frequency.
- 6PricewaterhouseCoopers LLP ratified as the independent registered public accounting firm for FY 2023.
- 7Shareholder proposal for an independent board chairman policy was not approved.